Nebenwirkungen · Invokana
Invokana 100 mg film-coated tablets Invokana 300 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 14–15
HOS-128165 · Präparat HOS-096517
14 In two other long-term studies in adults and in studies in adults conducted in the general diabetes population, no difference in fracture risk was observed with canagliflozin relative to control. In a second cardiovascular study (CANVAS-R) of 5,807 treated adult subjects with established or at least two risk factors for cardiovascular disease, the incidence rates of all adjudicated bone fracture were 1.1 and 1.3 events per 100 patient-years of follow-up to canagliflozin and placebo, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-18T14:12:00Z · SHA-256 7067553c5dc97aae664e9160409281edb3ba1df3f3d4e6376eabc1ce3744693b · Passage 2b14573e5f45c49719af2351503e5264898a3b30b94ff7f233f625aa7f8c972c · Zeichen 17775–18280 im Abschnitt